Pharmaceutical Regulatory Writing Services for Drug and Device Submissions

How Regulatory Reviews Differ From Academic Reviews

The distinction that matters most to a regulatory affairs team is not the search itself but the audit trail wrapped around it. An academic review is judged on novelty and interpretation. A regulatory review is judged on traceability and defensibility: can an assessor reconstruct exactly what you searched, when, why, what you excluded, and on what basis, months or years after the work was signed off. That standard changes the working method from the first day, because anything that cannot be reconstructed later has to be avoided from the start.

That difference shapes everything we do. A pre-specified protocol is written and version-controlled before the first database is queried, so scope, eligibility criteria, and appraisal rules are fixed in advance rather than adjusted to fit a preferred conclusion. Search strings are recorded verbatim per database with dates, hit counts, and platform versions. Screening is captured at both title-abstract and full-text stages with reasons for exclusion logged against named records. Every claim in the narrative maps back to an identified source. This is what an inspector or a notified body reviewer means when they ask for a reproducible and documented search, and it is the reason a submission-grade review costs more effort than a conventional literature survey. It also means the method is portable across your product portfolio: once a protocol template and search architecture are validated, they can be reapplied consistently to the next indication, device, or reporting cycle without relitigating first principles each time.

We build these reviews on the same rigorous foundation as our core our systematic review team, then layer the regulatory-specific documentation that dossiers, technical files, and safety reports require. Where a quantitative summary is appropriate and the underlying studies are sufficiently homogeneous, we can extend the work into formal pooled effect estimation and meta-analysis, aligning statistical principles with ICH E9 Statistical Principles for Clinical Trials (International Council for Harmonisation) and, where a common comparator is absent, conducting indirect treatment comparison in line with ISPOR Good Research Practices Task Force reports, always with pre-registered analysis choices rather than post hoc selection.

Systematic Literature Reviews Supporting Regulatory Dossiers

Regulatory submissions rely on a defensible synthesis of the existing evidence base, and a systematic literature review is the instrument that provides it. Within a dossier, such a review can support the clinical rationale, contextualize a product against the current standard of care, characterize the known safety profile of an active substance or device, and demonstrate that the applicant has surveyed the field comprehensively rather than selectively. This is where pharmaceutical regulatory writing services earn their keep: the document an assessor reads is only as persuasive as the evidence trail assembled behind it.

Our systematic literature review work for regulatory clients is anchored in three commitments. First, transparent appraisal: study quality and risk of bias are assessed with validated, pre-declared instruments so that the weight given to each source is justified, not asserted. Second, comprehensive and sensitive search design, because a regulatory reviewer will probe whether the search could plausibly have missed pivotal evidence. Our specialists in search strategy design and peer review construct and translate strings across bibliographic databases, trial registries, and grey-literature sources, and document the sensitivity-versus-precision trade-offs explicitly. Third, structured evidence synthesis that presents findings in a form an assessor can navigate, which is where our broader evidence synthesis and narrative summary capability supports mixed bodies of quantitative and qualitative data.

A regulatory literature review also has to anticipate the questions an assessor will ask before they are asked. We document the eligibility rationale in plain language, flag where the evidence base is sparse or heterogeneous rather than smoothing over it, and separate what the literature demonstrates from what it merely suggests. That candor is a feature, not a weakness: a submission that acknowledges the limits of its evidence and explains how they were handled is more credible than one that overstates certainty and invites challenge.

Where reporting standards apply, we report to the PRISMA 2020 Statement (Page et al., BMJ, 2021) so that the flow of records from identification through inclusion is visible at a glance, we structure conduct against the Cochrane Handbook for Systematic Reviews of Interventions, version 6.5 (Higgins JPT, Thomas J, et al., 2024), and we align appraisal language with GRADE for certainty of evidence (Guyatt et al., BMJ, 2008) where a certainty-of-evidence judgment strengthens the narrative, depending on the regulator.

Clinical Evaluation Report Literature Reviews Under EU MDR

For medical device manufacturers, the literature review is the evidentiary backbone of the Clinical Evaluation Report (CER). Under the EU Medical Device Regulation (EU MDR), Regulation (EU) 2017/745, clinical evaluation is a continuous, planned process, and the literature route remains central to demonstrating conformity, characterizing the clinical benefit-risk profile, and establishing the acceptability of residual risks.

We conduct CER literature reviews following the methodology set out in MEDDEV 2.7/1 Revision 4, structured around two distinct but linked objectives.

State-of-the-Art Reviews

A state-of-the-art literature review establishes the current clinical context: the recognized standard of care, alternative devices and treatments, applicable standards and guidance, and the accepted safety and performance benchmarks against which the subject device is judged. This is the reference frame that a notified body expects before any device-specific claim is assessed. We build the state of the art review as a self-contained, sourced narrative so that reviewers can see how the acceptance criteria for the device were derived rather than assumed.

Appraisal of Clinical Data

The second objective is the systematic identification and appraisal of clinical data relevant to the device itself and to equivalent devices where equivalence is claimed. We apply a documented appraisal method that grades the scientific validity, relevance, and weighting of each dataset, exactly as MEDDEV 2.7/1 Revision 4 anticipates, and we record the rationale for every inclusion and exclusion so the appraisal is reconstructable. The output feeds directly into the benefit-risk determination that the manufacturer's clinical evaluator and, ultimately, the notified body will scrutinize.

Manufacturers preparing a technical file frequently pair the CER literature work with formal medical and regulatory writing so that the narrative, tables, and evidence appendices are assembled to the standard the file requires.

Literature Reviews for Pharmacovigilance and Safety

On the medicinal-product side, structured literature searching is a standing obligation, not a one-time exercise. Under Good Pharmacovigilance Practices (GVP), marketing authorization holders must monitor the scientific literature systematically for safety information, and the review methodology has to be documented well enough to reconstruct on request.

Signal Detection Support

We provide signal detection support through reproducible literature searches designed to surface case reports, case series, observational findings, and emerging safety associations that may constitute a signal. The value of a defensible method here is direct: when a search is pre-specified and logged, the absence of a signal is as documentable as its presence, and both positions are inspection-ready.

PSUR Literature Searching

For the Periodic Safety Update Report (PSUR), we run interval literature searches on a fixed, repeatable protocol so that each reporting period is covered consistently and the cumulative safety picture is coherent across submissions. Search parameters, databases, date windows, and screening outcomes are recorded so that the PSUR literature searching methodology stands up to assessment and can be rerun identically in the next cycle.

Benefit-Risk Framing

Across both the device and medicinal-product contexts, safety evidence has to be placed in a benefit-risk frame rather than presented as an isolated list of findings. We structure the synthesis so that identified risks are weighed against demonstrated benefit in the specific intended-use population, giving the assessor a reasoned balance rather than an undifferentiated catalogue of literature. For products where access and value evidence also matter, this connects to our health technology assessment and market access work, though we keep the regulatory synthesis and the value synthesis methodologically distinct.

The Audit Trail Is the Deliverable

For inspection purposes, the review report and the evidence behind it are one object. We treat the full audit trail as a first-class deliverable, not a byproduct. That means the protocol, the dated search logs per source, the deduplication record, the screening decisions with exclusion reasons, the appraisal worksheets, the extraction tables, and the reference set are all preserved and cross-referenced so that any statement in the report can be walked back to its origin.

This discipline is what lets a submission survive a question that arrives eighteen months after sign-off: show us that this search would have found the pivotal study, and show us why these three records were excluded. When the reproducible and documented search and the transparent appraisal are captured properly the first time, that question is answered from the file, not reconstructed from memory.

Confidentiality, Purchase Orders, and Scope

Institutional work carries institutional requirements, and we structure engagements accordingly. Pharmaceutical, biotech, and medical device clients typically work with us under a non-disclosure agreement (NDA), against a purchase order, and within a written scope of work that names the deliverables, the reporting standard, the databases and date ranges, and the methodology reviewer accountable for the work. For this service that named PhD methodologist is Dr. Elena Vasquez.

We keep unpublished protocols, proprietary safety data, device technical information, and pre-submission strategy strictly confidential, and we align our documentation practices with the record-keeping expectations that quality and regulatory functions operate under. Pricing is scope-driven and fixed at quote; there is no per-region variation and no charge tied to the outcome of any submission.

To be unambiguous about what we do and do not provide: Research Gold delivers the evidence synthesis and the methodological rigor behind a regulatory literature review. We do not act as your regulatory representative, we do not make regulatory determinations, and we do not guarantee that any authority or notified body will accept a submission. What we stand behind is method: a defensible protocol, a search you can reproduce, an appraisal you can defend, and an audit trail you can hand to an inspector.

Start With a Scoped Conversation

Every regulatory engagement begins with scope, because the right method depends on whether you are building a CER under EU MDR, supporting a systematic literature review inside a dossier, standing up PSUR searching under GVP, or assembling a state-of-the-art review to frame a device claim. Tell us the submission context, the applicable standard, and the timeline, and we will map the methodology, the reporting format, and the documentation package to it. When you are ready, request a scoped quote and we will respond with a written proposal, matched with a methodologist experienced in your therapy area and submission type, and NDA and purchase-order terms on request. Published examples of the regulatory and evidence-synthesis work we stand behind are available in our ask to see our sample deliverables.